- Home
- QSG vs LPTX Comparison
QSG vs LPTX Comparison
Compare QSG & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSG
- LPTX
- Stock Information
- Founded
- QSG 2019
- LPTX 2011
- Country
- QSG China
- LPTX United States
- Employees
- QSG N/A
- LPTX N/A
- Industry
- QSG Other Consumer Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QSG Real Estate
- LPTX Health Care
- Exchange
- QSG Nasdaq
- LPTX Nasdaq
- Market Cap
- QSG 121.6M
- LPTX 119.6M
- IPO Year
- QSG 2023
- LPTX N/A
- Fundamental
- Price
- QSG $2.35
- LPTX $0.53
- Analyst Decision
- QSG
- LPTX Buy
- Analyst Count
- QSG 0
- LPTX 3
- Target Price
- QSG N/A
- LPTX $8.50
- AVG Volume (30 Days)
- QSG 113.2K
- LPTX 1.4M
- Earning Date
- QSG 03-06-2025
- LPTX 03-17-2025
- Dividend Yield
- QSG 8.63%
- LPTX N/A
- EPS Growth
- QSG 662.58
- LPTX N/A
- EPS
- QSG 1.03
- LPTX N/A
- Revenue
- QSG $532,696,414.00
- LPTX N/A
- Revenue This Year
- QSG N/A
- LPTX N/A
- Revenue Next Year
- QSG N/A
- LPTX N/A
- P/E Ratio
- QSG $2.32
- LPTX N/A
- Revenue Growth
- QSG 13.53
- LPTX N/A
- 52 Week Low
- QSG $1.47
- LPTX $0.50
- 52 Week High
- QSG $6.22
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- QSG 53.97
- LPTX 17.79
- Support Level
- QSG $2.29
- LPTX $2.03
- Resistance Level
- QSG $2.48
- LPTX $2.39
- Average True Range (ATR)
- QSG 0.20
- LPTX 0.24
- MACD
- QSG 0.04
- LPTX -0.24
- Stochastic Oscillator
- QSG 75.02
- LPTX 0.70
About QSG QuantaSing Group Limited
QuantaSing Group Ltd is a learning service provider in China's adult learning market for personal interest courses. It offers easy-to-understand, affordable, and accessible online courses to adult learners under various brands, including QiNiu, Kelly, and QianChi among others empowering them to pursue personal development. The company offers courses for various domains such as financial literacy, skill upgrading, recreation, and leisure which are offered in live large-class dual-instructor mode, online community-based training camp mode, and in live lecture, one-on-one tutoring mode. Its segments are; Learning service and others which derives key revenue, and Consumer business. Geographically, the company generates all of its revenue from the People's Republic of China.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .